CMC Biologics has received renewal of its manufacturing and importation authorization (MIA) for Good Manufacturing Practice (cGMP) production of clinical and commercial manufacturing from the Danish Medicines Agency (DKMA), a division of the Danish Health and Medicines Authority.
The DKMA inspected CMC Biologics’ optimized manufacturing and testing facilities in Copenhagen, Denmark in late May, and issued the certificate based on the positive outcome of the inspection.
"This important regulatory milestone helps drives our strategy to satisfy our customers’ growing clinical and commercial cGMP manufacturing requirements, and takes this site to the next level as a global leader in commercial production of protein therapeutics,” said Patricio Massera,
General Manager of CMC Biologics Copenhagen. “We are committed to the highest quality standards and extremely pleased with the results of the agency’s inspection.”
CMC Biologics made an important capital investment in its biopharmaceutical manufacturing facility which optimizes segregation of unit operations and improves flow of materials and personnel.
The enhanced layout now maintains a fully unidirectional return corridor and exit airlocks to achieve exceptional manufacturing quality standards.
The updated MIA is available on the EudraGMP database at http://eudragmp.ema.europa.eu; authorization number 26415.
Massera adds, “Our vision is to be considered the global market leader of customer satisfaction for contract biopharmaceutical process development and manufacturing services. This facility expansion and successful regulatory inspection represents another step toward making that vision a reality.”